Literature DB >> 22482117

Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

T C Nichols1, H W G Franck, C T Franck, N De Friess, R A Raymer, E P Merricks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22482117      PMCID： PMC3360416          DOI： 10.1111/j.1538-7836.2011.04613.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  20 in total

1.  On a Method of Determining the Condition of Blood Coagulability for Clinical and Experimental Purposes, and on the Effect of the Administration of Calcium Salts in Haemophilia and Actual or Threatened Haemorrhage: [Preliminary Communication].

Authors:  A E Wright
Journal:  Br Med J       Date:  1893-07-29

2.  The value and the limitations of the coagulation time in the study of the hemorrhagic diseases.

Authors:  A J QUICK; C R HONORATO; M STEFANINI
Journal:  Blood       Date:  1948-10       Impact factor: 22.113

3.  SILICONES AND BLOOD COAGULATION.

Authors:  L B Jaques; E Fidlar; E T Feldsted; A G Macdonald
Journal:  Can Med Assoc J       Date:  1946-07       Impact factor: 8.262

4.  A simple assay for human factor IX: use of canine hemophilia B plasma as substrate.

Authors:  J C Goldsmith; K S Chung; H R Roberts
Journal:  Thromb Res       Date:  1978-03       Impact factor: 3.944

5.  Development of a sensitive and rapid chromogenic factor IX assay for clinical use.

Authors:  R Wagenvoord; H Hendrix; T Tran; H C Hemker
Journal:  Haemostasis       Date:  1990

6.  Isolation and characterization of canine factor IX.

Authors:  Y Sugahara; J Catalfamo; M Brooks; E Hitomi; S P Bajaj; K Kurachi
Journal:  Thromb Haemost       Date:  1996-03       Impact factor: 5.249

7.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.

Authors:  Roland W Herzog; Paul A Fields; Valder R Arruda; Jeff O Brubaker; Elina Armstrong; Darryl McClintock; Dwight A Bellinger; Linda B Couto; Timothy C Nichols; Katherine A High
Journal:  Hum Gene Ther       Date:  2002-07-20       Impact factor: 5.695

8.  In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.

Authors:  M A Kay; S Rothenberg; C N Landen; D A Bellinger; F Leland; C Toman; M Finegold; A R Thompson; M S Read; K M Brinkhous
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

9.  Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

Authors:  K M Brinkhous; J L Sigman; M S Read; P F Stewart; K P McCarthy; G A Timony; S D Leppanen; B J Rup; J C Keith; P D Garzone; R G Schaub
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

10.  Binding of coagulation factors IX and X to the endothelial cell surface.

Authors:  R L Heimark; S M Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1983-03-16       Impact factor: 3.575
View more
  9 in total

1.  Quantifying vitamin K-dependent holoprotein compaction caused by differential γ-carboxylation using high-pressure size exclusion chromatography.

Authors:  Nicholas C Vanderslice; Amanda S Messer; Kanagasabai Vadivel; S Paul Bajaj; Martin Phillips; Mostafa Fatemi; Weijie Xu; William H Velander
Journal:  Anal Biochem       Date:  2015-03-22       Impact factor: 3.365

2.  Portal vein delivery of viral vectors for gene therapy for hemophilia.

Authors:  Alexandra Sherman; Alexander Schlachterman; Mario Cooper; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Roland W Herzog; Timothy C Nichols
Journal:  Methods Mol Biol       Date:  2014

3.  The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.

Authors:  Jonathan D Finn; Timothy C Nichols; Nikolaos Svoronos; Elizabeth P Merricks; Dwight A Bellenger; Shangshen Zhou; Paolo Simioni; Katherine A High; Valder R Arruda
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

Review 4.  A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

Authors:  Mallory R Scola; Leslie M Baggesen; Tim C Nichols; Nigel S Key; Caterina M Gallippi
Journal:  Thromb Res       Date:  2012-03-08       Impact factor: 3.944

5.  Liver-directed lentiviral gene therapy in a dog model of hemophilia B.

Authors:  Alessio Cantore; Marco Ranzani; Cynthia C Bartholomae; Monica Volpin; Patrizia Della Valle; Francesca Sanvito; Lucia Sergi Sergi; Pierangela Gallina; Fabrizio Benedicenti; Dwight Bellinger; Robin Raymer; Elizabeth Merricks; Francesca Bellintani; Samia Martin; Claudio Doglioni; Armando D'Angelo; Thierry VandenDriessche; Marinee K Chuah; Manfred Schmidt; Timothy Nichols; Eugenio Montini; Luigi Naldini
Journal:  Sci Transl Med       Date:  2015-03-04       Impact factor: 17.956

6.  Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Authors:  Lily M Du; Paquita Nurden; Alan T Nurden; Timothy C Nichols; Dwight A Bellinger; Eric S Jensen; Sandra L Haberichter; Elizabeth Merricks; Robin A Raymer; Juan Fang; Sevasti B Koukouritaki; Paula M Jacobi; Troy B Hawkins; Kenneth Cornetta; Qizhen Shi; David A Wilcox
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.

Authors:  David M Markusic; Timothy C Nichols; Elizabeth P Merricks; Brett Palaschak; Irene Zolotukhin; Damien Marsic; Sergei Zolotukhin; Arun Srivastava; Roland W Herzog
Journal:  J Transl Med       Date:  2017-05-01       Impact factor: 5.531

8.  Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce.

Authors:  Roland W Herzog; Timothy C Nichols; Jin Su; Bei Zhang; Alexandra Sherman; Elizabeth P Merricks; Robin Raymer; George Q Perrin; Mattias Häger; Bo Wiinberg; Henry Daniell
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

9.  Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.

Authors:  Timothy C Nichols; Howard Levy; Elizabeth P Merricks; Robin A Raymer; Martin L Lee
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.